Oxford Closes $20MM Debt Facility with Inhibrx
Oxford Finance announced the closing of a $20 million senior secured term loan agreement with Inhibrx, a biologic immunotherapeutic company focused on the treatment of unmet medical needs in oncology, infectious disease and inflammatory conditions.
Proceeds of the loan will enable Inhibrx to continue to advance its extensive portfolio of therapeutics.
“We are pleased to provide financing to Inhibrx to support the development of their therapeutic pipeline addressing various clinical targets,” said Christopher A. Herr, managing director for Oxford Finance. “The company currently has a promising licensing agreement with a major biopharmaceutical company for one of its assets, and has a unique business model that enables a cost effective and accelerated process for advancing other therapeutics into the clinic.”
“We appreciate Oxford’s support of our efforts to develop innovative therapeutics for patients in need of better treatment options,” said Mark Lappe, chief executive officer of Inhibrx.
Inhibrx is a biologic immunotherapeutic company focused on the treatment of unmet medical needs.